Share

(...) "The European Medicines Agency (European Union’s FDA equivalent) has assented to Repligen’s proposal of a phase I clinical trial of RG2833 in FA patients. Repligen is now seeking the permission of the Italian government and the ethics committee at the Italian hospital, in Turin, where the trial is proposed. If that permission is granted, the phase I trial of RG2833 in FA patients should commence in Italy by year’s end." (...)